Literature DB >> 24296701

Prostate cancer: Could sensitive PSA assays expedite salvage radiotherapy?

John B Eifler1, Michael S Cookson2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24296701     DOI： 10.1038/nrurol.2013.276

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  8 in total

1.  Treat now or later: the dilemma of postoperative radiotherapy.

Authors:  Adam S Kibel
Journal:  Eur Urol       Date:  2011-12-03       Impact factor: 20.096

2.  Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.

Authors:  Maria C Mir; Jianbo Li; Joseph C Klink; Michael W Kattan; Eric A Klein; Andrew J Stephenson
Journal:  Eur Urol       Date:  2013-08-20       Impact factor: 20.096

3.  Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study.

Authors:  Herbert Lepor; Carol D Cheli; Robert P Thiel; Samir S Taneja; Juliana Laze; Dan W Chan; Lori J Sokoll; Leslie Mangold; Alan W Partin
Journal:  BJU Int       Date:  2011-10-12       Impact factor: 5.588

4.  Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

Authors:  Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

5.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

Authors:  Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544

6.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin M Slawin; Eric A Klein; Mitchell S Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard K Valicenti; Deborah A Kuban; Alan Pollack
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

7.  Comparison of models to predict clinical failure after radical prostatectomy.

Authors:  Scott E Eggener; Andrew J Vickers; Angel M Serio; Michael J Donovan; Faisal M Khan; Valentina Bayer-Zubek; David Verbel; Carlos Cordon-Cardo; Victor E Reuter; Fernando J Bianco; Peter T Scardino
Journal:  Cancer       Date:  2009-01-15       Impact factor: 6.860

8.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.

Authors:  Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford
Journal:  J Urol       Date:  2009-01-23       Impact factor: 7.450
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.